Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Raw Materials (2020 - 2025)

Cytek Biosciences' Raw Materials history spans 6 years, with the latest figure at $20.4 million for Q4 2025.

  • For Q4 2025, Raw Materials fell 9.43% year-over-year to $20.4 million; the TTM value through Dec 2025 reached $20.4 million, down 9.43%, while the annual FY2025 figure was $20.4 million, 9.43% down from the prior year.
  • Raw Materials reached $20.4 million in Q4 2025 per CTKB's latest filing, down from $24.7 million in the prior quarter.
  • In the past five years, Raw Materials ranged from a high of $42.2 million in Q1 2023 to a low of $15.4 million in Q3 2021.
  • Average Raw Materials over 5 years is $26.9 million, with a median of $25.8 million recorded in 2022.
  • Peak YoY movement for Raw Materials: skyrocketed 99.18% in 2023, then tumbled 36.81% in 2024.
  • A 5-year view of Raw Materials shows it stood at $17.3 million in 2021, then soared by 56.0% to $26.9 million in 2022, then soared by 32.66% to $35.7 million in 2023, then crashed by 36.81% to $22.6 million in 2024, then fell by 9.43% to $20.4 million in 2025.
  • Per Business Quant, the three most recent readings for CTKB's Raw Materials are $20.4 million (Q4 2025), $24.7 million (Q3 2025), and $24.9 million (Q2 2025).